Larotrectinib (Vitrakvi)

Targeted TherapyApproved for: NSCLCBiomarker: NTRK Larotrectinib (Vitrakvi) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go...
|
May 27, 2021
|